Aquestive Therapeutics (AQST) Change in Accured Expenses (2017 - 2026)

Aquestive Therapeutics' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 0.97% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at $3.0 million (up 225.47% YoY), while the FY2025 annual figure was $3.0 million, up 303.22% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.8 million, down from $5.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.1 million in Q4 2025, with the low at -$4.0 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$25000.0 (2022), against an average of -$362352.9.
• Peak annual rise in Change in Accured Expenses reached 3916.0% in 2023, while the deepest fall reached 160.3% in 2023.
• Aquestive Therapeutics' Change in Accured Expenses stood at -$25000.0 in 2022, then surged by 3916.0% to $954000.0 in 2023, then dropped by 3.98% to $916000.0 in 2024, then surged by 455.68% to $5.1 million in 2025, then plunged by 155.07% to -$2.8 million in 2026.
• Business Quant data shows AQST's Change in Accured Expenses at -$2.8 million in Q1 2026, $5.1 million in Q4 2025, and $118000.0 in Q3 2025.